Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome

被引：2
|
作者：
Cocorocchio, E. [1 ]
Nezi, L. [2 ]
Gandini, S. [2 ]
Manzo, T. [2 ]
Mazzarella, L. [2 ]
Lotti, F. [2 ]
Pala, L. [3 ]
Gnagnarella, P. [2 ]
Conforti, F. [3 ]
Pennacchioli, E. [4 ]
Fierro, M. T. [5 ]
Ribero, S. [6 ]
Senetta, R. [5 ]
Picciotto, F. [7 ]
Caliendo, V. [7 ]
Quaglino, P. [5 ]
Mazzarol, G. [3 ,8 ]
Orsolini, G. M. [4 ]
Prestianni, P. [4 ]
Ferrucci, P. F. [9 ]
机构：
[1] IRCCS, Ist Europeo Oncol, Hematoncol, Milan, Italy
[2] IRCCS, Ist Europeo Oncol, Experimental Oncol, Milan, Italy
[3] IRCCS, Ist Europeo Oncol, Med Oncol Melanoma Sarcoma & Rare Tumors, Milan, Italy
[4] IRCCS, Ist Europeo Oncol, Sarcoma & Rare Tumors, Surg Melanoma, Milan, Italy
[5] AOU Citta Salute & Sci Torino, Med Sci, Turin, Italy
[6] Azienda Osped Univ San Giovanni Battista Torino, Med Sci Dept, Turin, Italy
[7] AOU Citta Salute & Sci Torino Turin, Dermatol Surg, Turin, Italy
[8] IRCCS, Ist Europeo Oncol, Pathol & Lab Med, Milan, Italy
[9] IRCCS, Ist Europeo Oncol, Oncol Dept, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1072P
引用
收藏
页码：S889 / S890
页数：2
相关论文
共 50 条
  • [21] Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
    Ribas, Antoni
    Martin-Algarra, Salvador
    Bhatia, Shailender
    Hwu, Wen-Jen
    Slingluff, Craig L.
    Sharfman, William H.
    Hodi, F. Stephen
    Urba, Walter J.
    Luke, Jason J.
    Haanen, John B.
    Callahan, Margaret K.
    Wolchok, Jedd D.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Young, Tina C.
    Qureshi, Anila
    Horak, Christine E.
    CANCER RESEARCH, 2017, 77
  • [22] Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Chapman, Paul B.
    Jayaprakasam, Vetri Sudar
    Panageas, Katherine S.
    Callahan, Margaret
    Postow, Michael A.
    Shoushtari, Alexander N.
    Wolchok, Jedd D.
    Warner, Allison Betof
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [23] Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma
    Kobayashi, Y.
    Arai, H.
    Honda, M.
    CURRENT ONCOLOGY, 2020, 27 (04) : 225 - 228
  • [24] Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
    Long, Georgina V.
    Larkin, James
    Schadendorf, Dirk
    Grob, Jean-Jacques
    Lao, Christopher D.
    Marquez-Rodas, Ivan
    Wagstaff, John
    Lebbe, Celeste
    Pigozzo, Jacopo
    Robert, Caroline
    Ascierto, Paolo A.
    Atkinson, Victoria
    Postow, Michael A.
    Atkins, Michael B.
    Sznol, Mario
    Callahan, Margaret K.
    Topalian, Suzanne L.
    Sosman, Jeffrey A.
    Kotapati, Srividya
    Thakkar, Pratik K.
    Ritchings, Corey
    Benito, Melanie Pe
    Re, Sandra
    Soleymani, Samira
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (08)
  • [25] Nico: Real World Evidence in Advanced Melanoma; A National Prospective Non-Interventional Study of Nivolumab Monotherapy or in Combination with Ipilimumab in Patients with Advanced Melanoma and in Patients with Adjuvant Nivolumab Therapy
    Schadendorf, Dirk
    Eigertler, Thomas
    Mohr, Peter
    Weichenthal, Michael
    Goeppner, Daniela
    Haferkamp, Sebastian
    Herber, Martin
    Meier, Friedegund
    Meiss, Frank
    Pfoehler, Claudia
    Schneider, Stefan W.
    Terheyden, Patrick
    Ulrich, Lens
    Utikal, Jochen
    Weishaupt, Carsten
    Gutzmer, Ralf
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 175 - 175
  • [26] PKPD relationship of ipilimumab plus nivolumab combination in patients with advanced melanoma
    Goldwirt, L.
    Louveau, B.
    Liv, T.
    Baroudjian, B.
    Allayous, C.
    Da Meda, L.
    Delyon, J.
    Sauvageon, H.
    Lebbe, C.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 38 - 38
  • [27] Cutaneous manifestations of ipilimumab, nivolumab and pembrolizumab therapy in patients with advanced melanoma
    Kumar, Anagha Bangalore
    Bryce, Alan
    Vishnu, Prakash
    Markovic, Svetomir
    McEvoy, Marian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB188 - AB188
  • [28] Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma
    Tetu, Pauline
    Mangana, Joanna
    Dummer, Reinhard
    Dutriaux, Caroline
    Beneton, Nathalie
    Dalle, Stephane
    Meyer, Nicolas
    Oriano, Bastien
    Michielin, Olivier
    Lebbe, Celeste
    EUROPEAN JOURNAL OF CANCER, 2018, 93 : 147 - 149
  • [29] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. -J.
    Cowey, C. L.
    Lao, C. D.
    Wagstaff, J.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Hogg, D.
    Haanen, J.
    Carlino, M. S.
    Bechter, O.
    Maio, M.
    Marquez-Rodas, I.
    Guidoboni, M.
    McArthur, G.
    Lebbe, C.
    Ascierto, P. A.
    Long, G. V.
    Cebon, J.
    Sosman, J.
    Postow, M. A.
    Callahan, M. K.
    Walker, D.
    Rollin, L.
    Bhore, R.
    Hodi, F. S.
    Larkin, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14): : 1345 - 1356
  • [30] Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma
    Sullivan, Ryan Joseph
    LANCET, 2020, 395 (10236): : 1524 - 1525
12345